kcgi cmo
Scope
Date
~
-
Bio & Pharma
Samsung Biologics reaches record-breaking annual orders
Samsung Biologics Co., the world’s top contract manufacturing organization (CMO) by capacity, surpassed the annual contract manufacturing orde...
Nov 28, 2023 (Gmt+09:00)
-
Corporate governance
Hyundai Group chair exits Schindler-invested unit board
Hyundai Group's chairwoman on Friday resigned from the board of its elevator unit, whose No. 2 shareholder is Schindler Holding AG, amid mounting sh...
Nov 17, 2023 (Gmt+09:00)
-
Korean stock market
KCGI Asset Management appoints former KIS head as new CMO
South Korea’s KCGI Asset Management, formerly Meritz Asset Management, announced on Friday that it has hired Cho Won-bok, former division head...
Aug 11, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience buys 6.5 million Novavax shares for $83.4 million
SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vacc...
Aug 09, 2023 (Gmt+09:00)
-
Shareholder activism
KCGI’s ascent to intensify family feud over DB control; DB stocks rally
A sibling feud over management control of DB Group is expected to intensify following the ascent of South Korean activist fund Korea Corporate Gover...
Apr 04, 2023 (Gmt+09:00)
-
Shareholder activism
S.Korean activist fund KCGI eyes foundry DB HiTek buyout
Korea Corporate Governance Improvement Fund (KCGI) is eyeing a controlling stake in DB HiTek Co. as the activist fund became the second-largest shar...
Mar 31, 2023 (Gmt+09:00)
-
Korean chipmakers
Chip foundry DB HiTek's stock near 10-month peak on activist fund
South Korean leading foundry chipmaker DB HiTek’s stock price hit a near 10-month high this week as a domestic activist fund bought a stake to...
Mar 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics bags $183 million CMO order from Pfizer
Samsung Biologics Co., the world’s No. 1 contract drug maker in terms of production capacity, has won a $182.7 million contract manufacturing ...
Mar 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Feb 20, 2023 (Gmt+09:00)
-
Shareholder activism
Activist fund KCGI to sell Osstem stake to UCK, MBK Partners
Korea Corporate Governance Improvement Fund (KCGI), one of the country’s most aggressive shareholder activists, plans to sell its stake in Oss...
Feb 10, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
MBK, Unison to expand Osstem Implant's target reach beyond China
South Korean private equity firm Unison Capital Korea is set to focus on boosting the corporate value of Osstem Implant Co., once the PE manager and...
Feb 03, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Korean activist fund KCGI buys Meritz Asset Management
A consortium led by Korea Corporate Governance Improvement Fund (KCGI), a local activist fund, said on Jan. 9 it signed a share purchase agreement l...
Jan 09, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Korea's Meritz Group likely to sell off its asset management arm
South Korea’s Meritz Financial Group Inc. is poised to sell off its subsidiary Meritz Asset Management Co., The Korea Economic Daily understoo...
Nov 01, 2022 (Gmt+09:00)
-
Bio & Pharma
Korea's Samsung Biologics signs $296 mn CMO deal with GSK
South Korea’s Samsung Biologics Co. has signed a $296.1 million deal to supply biopharmaceutical products to UK-based multinational pharma gia...
Oct 21, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Biologics signs $81 mn CMO deal with Novartis
South Korea’s Samsung Biologics Co. has inked an $81 million contract manufacturing deal with Novartis, the world’s fifth-largest pharma...
Jun 07, 2022 (Gmt+09:00)
language -
Private equity
Lessons learned from activist fund’s KAL exit
Activist fund Korea Corporate Governance Improvement Fund (KCGI) recently exited its investment in Hanjin KAL Co., the parent company of Korean Air ...
Apr 05, 2022 (Gmt+09:00)
-
COVID-19
SK seeks to make Pfizer, Merck COVID-19 pills in CMO deals
SK Inc., the investment and holding company of South Korea’s SK Group, is seeking to make COVID-19 treatment pills developed by Pfizer Inc. an...
Nov 17, 2021 (Gmt+09:00)
language -
Pharamaceuticals
Korea’s Genome & Company aims US CMO market
South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into...
Sep 09, 2021 (Gmt+09:00)
language -
Mergers & Acquisitions
Korean activist fund KCGI joins in consortium to buy Ssangyong
A South Korean electric bus maker Edison Motors Co. added the activist fund Korea Corporate Government Improvement Fund (KCGI) as a financial invest...
Aug 09, 2021 (Gmt+09:00)
language -
COVID-19
CureVac may pick Korea as Asian base for COVID vaccine production
German biopharmaceutical company CureVac N.V. may choose South Korea as one of its global production bases for the COVID-19 vaccine following Korean...
Jun 16, 2021 (Gmt+09:00)
language -
Korean food
SK acquires 70% stake in Yposkesi to jump into cell, gene CMO business
SK Inc., the holding and investment company of SK Group, South Korea’s third-largest conglomerate, has acquired a 70% stake in Yposkesi, a Fre...
Mar 31, 2021 (Gmt+09:00)
-
Biopharma CMO
Moderna deal shows Korea’s prowess as global hub for biopharma CMO
South Korea is emerging as a global hub for the contract manufacturing of biopharmaceuticals following its latest deal to procure COVID-19 vaccines ...
Dec 30, 2020 (Gmt+09:00)
language -
Mergers & Acquisitions
SK in talks to buy French biologics contract manufacturer
SK Holdings is in the early stages of negotiations to acquire France’s biologic contract manufacturing organization (CMO) Yposkesi, in a move ...
Dec 17, 2020 (Gmt+09:00)
language -
Shareholder activism
Local activist fund KCGI opposes Korean Air's sale of in-flight businesses
Korea Corporate Governance Improvement (KCGI), a local activist private equity fund, is unhappy with Korean Air Lines Co. Ltd's decision to sell ...
Jul 17, 2020 (Gmt+09:00)